Effects of N‐acetylcysteine on oxidative stress biomarkers, depression, and anxiety symptoms in patients with multiple sclerosis
Aim N‐acetylcysteine (NAC), a thiol‐containing antioxidant and glutathione (GSH) precursor, attenuates oxidative stress, and possibly improves psychiatric disorders. This study aimed to evaluate the effects of oral NAC on oxidative stress, depression, and anxiety symptoms in patients with multiple s...
Saved in:
Published in | Neuropsychopharmacology reports Vol. 43; no. 3; pp. 382 - 390 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
John Wiley & Sons, Inc
01.09.2023
John Wiley and Sons Inc Wiley |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Aim
N‐acetylcysteine (NAC), a thiol‐containing antioxidant and glutathione (GSH) precursor, attenuates oxidative stress, and possibly improves psychiatric disorders. This study aimed to evaluate the effects of oral NAC on oxidative stress, depression, and anxiety symptoms in patients with multiple sclerosis (MS).
Methods
This clinical trial was conducted on 42 MS patients randomly assigned to intervention (n = 21) and control (n = 21) groups. The intervention group received 600 mg of NAC twice daily for 8 weeks, and the control group received a placebo with the same prescription form. An analysis of serum malondialdehyde (MDA), serum nitric oxide (NO), and erythrocyte GSH was carried out on both groups, along with a complete blood count. The Hospital Anxiety and Depression Scale (HADS) was used to assess symptoms of depression (HADS‐D) and anxiety (HADS‐A).
Results
Compared to the control group, NAC consumption significantly decreased serum MDA concentrations (−0.33 [−5.85–2.50] vs. 2.75 [−0.25–5.22] μmol/L; p = 0.03) and HADS‐A scores (−1.6 ± 2.67 vs. 0.33 ± 2.83; p = 0.02). No significant changes were observed in serum NO concentrations, erythrocyte GSH levels, and HADS‐D scores (p > 0.05).
Conclusions
Based on the findings of the present study, NAC supplementation for 8 weeks decreased lipid peroxidation and improved anxiety symptoms in MS patients. The aforementioned results suggest that adjunctive therapy with NAC can be considered an effective strategy for MS management. Further randomized controlled studies are warranted.
N‐acetylcysteine (NAC) supplementation for 8 weeks decreased lipid peroxidation and improved anxiety symptoms in multiple sclerosis (MS) patients. The aforementioned results suggest that adjunctive therapy with NAC can be considered an effective strategy for MS management. |
---|---|
AbstractList | N-acetylcysteine (NAC), a thiol-containing antioxidant and glutathione (GSH) precursor, attenuates oxidative stress, and possibly improves psychiatric disorders. This study aimed to evaluate the effects of oral NAC on oxidative stress, depression, and anxiety symptoms in patients with multiple sclerosis (MS).
This clinical trial was conducted on 42 MS patients randomly assigned to intervention (n = 21) and control (n = 21) groups. The intervention group received 600 mg of NAC twice daily for 8 weeks, and the control group received a placebo with the same prescription form. An analysis of serum malondialdehyde (MDA), serum nitric oxide (NO), and erythrocyte GSH was carried out on both groups, along with a complete blood count. The Hospital Anxiety and Depression Scale (HADS) was used to assess symptoms of depression (HADS-D) and anxiety (HADS-A).
Compared to the control group, NAC consumption significantly decreased serum MDA concentrations (-0.33 [-5.85-2.50] vs. 2.75 [-0.25-5.22] μmol/L; p = 0.03) and HADS-A scores (-1.6 ± 2.67 vs. 0.33 ± 2.83; p = 0.02). No significant changes were observed in serum NO concentrations, erythrocyte GSH levels, and HADS-D scores (p > 0.05).
Based on the findings of the present study, NAC supplementation for 8 weeks decreased lipid peroxidation and improved anxiety symptoms in MS patients. The aforementioned results suggest that adjunctive therapy with NAC can be considered an effective strategy for MS management. Further randomized controlled studies are warranted. Aim N‐acetylcysteine (NAC), a thiol‐containing antioxidant and glutathione (GSH) precursor, attenuates oxidative stress, and possibly improves psychiatric disorders. This study aimed to evaluate the effects of oral NAC on oxidative stress, depression, and anxiety symptoms in patients with multiple sclerosis (MS). Methods This clinical trial was conducted on 42 MS patients randomly assigned to intervention (n = 21) and control (n = 21) groups. The intervention group received 600 mg of NAC twice daily for 8 weeks, and the control group received a placebo with the same prescription form. An analysis of serum malondialdehyde (MDA), serum nitric oxide (NO), and erythrocyte GSH was carried out on both groups, along with a complete blood count. The Hospital Anxiety and Depression Scale (HADS) was used to assess symptoms of depression (HADS‐D) and anxiety (HADS‐A). Results Compared to the control group, NAC consumption significantly decreased serum MDA concentrations (−0.33 [−5.85–2.50] vs. 2.75 [−0.25–5.22] μmol/L; p = 0.03) and HADS‐A scores (−1.6 ± 2.67 vs. 0.33 ± 2.83; p = 0.02). No significant changes were observed in serum NO concentrations, erythrocyte GSH levels, and HADS‐D scores (p > 0.05). Conclusions Based on the findings of the present study, NAC supplementation for 8 weeks decreased lipid peroxidation and improved anxiety symptoms in MS patients. The aforementioned results suggest that adjunctive therapy with NAC can be considered an effective strategy for MS management. Further randomized controlled studies are warranted. Aim N‐acetylcysteine (NAC), a thiol‐containing antioxidant and glutathione (GSH) precursor, attenuates oxidative stress, and possibly improves psychiatric disorders. This study aimed to evaluate the effects of oral NAC on oxidative stress, depression, and anxiety symptoms in patients with multiple sclerosis (MS). Methods This clinical trial was conducted on 42 MS patients randomly assigned to intervention (n = 21) and control (n = 21) groups. The intervention group received 600 mg of NAC twice daily for 8 weeks, and the control group received a placebo with the same prescription form. An analysis of serum malondialdehyde (MDA), serum nitric oxide (NO), and erythrocyte GSH was carried out on both groups, along with a complete blood count. The Hospital Anxiety and Depression Scale (HADS) was used to assess symptoms of depression (HADS‐D) and anxiety (HADS‐A). Results Compared to the control group, NAC consumption significantly decreased serum MDA concentrations (−0.33 [−5.85–2.50] vs. 2.75 [−0.25–5.22] μmol/L; p = 0.03) and HADS‐A scores (−1.6 ± 2.67 vs. 0.33 ± 2.83; p = 0.02). No significant changes were observed in serum NO concentrations, erythrocyte GSH levels, and HADS‐D scores (p > 0.05). Conclusions Based on the findings of the present study, NAC supplementation for 8 weeks decreased lipid peroxidation and improved anxiety symptoms in MS patients. The aforementioned results suggest that adjunctive therapy with NAC can be considered an effective strategy for MS management. Further randomized controlled studies are warranted. N‐acetylcysteine (NAC) supplementation for 8 weeks decreased lipid peroxidation and improved anxiety symptoms in multiple sclerosis (MS) patients. The aforementioned results suggest that adjunctive therapy with NAC can be considered an effective strategy for MS management. N-acetylcysteine (NAC), a thiol-containing antioxidant and glutathione (GSH) precursor, attenuates oxidative stress, and possibly improves psychiatric disorders. This study aimed to evaluate the effects of oral NAC on oxidative stress, depression, and anxiety symptoms in patients with multiple sclerosis (MS).AIMN-acetylcysteine (NAC), a thiol-containing antioxidant and glutathione (GSH) precursor, attenuates oxidative stress, and possibly improves psychiatric disorders. This study aimed to evaluate the effects of oral NAC on oxidative stress, depression, and anxiety symptoms in patients with multiple sclerosis (MS).This clinical trial was conducted on 42 MS patients randomly assigned to intervention (n = 21) and control (n = 21) groups. The intervention group received 600 mg of NAC twice daily for 8 weeks, and the control group received a placebo with the same prescription form. An analysis of serum malondialdehyde (MDA), serum nitric oxide (NO), and erythrocyte GSH was carried out on both groups, along with a complete blood count. The Hospital Anxiety and Depression Scale (HADS) was used to assess symptoms of depression (HADS-D) and anxiety (HADS-A).METHODSThis clinical trial was conducted on 42 MS patients randomly assigned to intervention (n = 21) and control (n = 21) groups. The intervention group received 600 mg of NAC twice daily for 8 weeks, and the control group received a placebo with the same prescription form. An analysis of serum malondialdehyde (MDA), serum nitric oxide (NO), and erythrocyte GSH was carried out on both groups, along with a complete blood count. The Hospital Anxiety and Depression Scale (HADS) was used to assess symptoms of depression (HADS-D) and anxiety (HADS-A).Compared to the control group, NAC consumption significantly decreased serum MDA concentrations (-0.33 [-5.85-2.50] vs. 2.75 [-0.25-5.22] μmol/L; p = 0.03) and HADS-A scores (-1.6 ± 2.67 vs. 0.33 ± 2.83; p = 0.02). No significant changes were observed in serum NO concentrations, erythrocyte GSH levels, and HADS-D scores (p > 0.05).RESULTSCompared to the control group, NAC consumption significantly decreased serum MDA concentrations (-0.33 [-5.85-2.50] vs. 2.75 [-0.25-5.22] μmol/L; p = 0.03) and HADS-A scores (-1.6 ± 2.67 vs. 0.33 ± 2.83; p = 0.02). No significant changes were observed in serum NO concentrations, erythrocyte GSH levels, and HADS-D scores (p > 0.05).Based on the findings of the present study, NAC supplementation for 8 weeks decreased lipid peroxidation and improved anxiety symptoms in MS patients. The aforementioned results suggest that adjunctive therapy with NAC can be considered an effective strategy for MS management. Further randomized controlled studies are warranted.CONCLUSIONSBased on the findings of the present study, NAC supplementation for 8 weeks decreased lipid peroxidation and improved anxiety symptoms in MS patients. The aforementioned results suggest that adjunctive therapy with NAC can be considered an effective strategy for MS management. Further randomized controlled studies are warranted. Abstract Aim N‐acetylcysteine (NAC), a thiol‐containing antioxidant and glutathione (GSH) precursor, attenuates oxidative stress, and possibly improves psychiatric disorders. This study aimed to evaluate the effects of oral NAC on oxidative stress, depression, and anxiety symptoms in patients with multiple sclerosis (MS). Methods This clinical trial was conducted on 42 MS patients randomly assigned to intervention (n = 21) and control (n = 21) groups. The intervention group received 600 mg of NAC twice daily for 8 weeks, and the control group received a placebo with the same prescription form. An analysis of serum malondialdehyde (MDA), serum nitric oxide (NO), and erythrocyte GSH was carried out on both groups, along with a complete blood count. The Hospital Anxiety and Depression Scale (HADS) was used to assess symptoms of depression (HADS‐D) and anxiety (HADS‐A). Results Compared to the control group, NAC consumption significantly decreased serum MDA concentrations (−0.33 [−5.85–2.50] vs. 2.75 [−0.25–5.22] μmol/L; p = 0.03) and HADS‐A scores (−1.6 ± 2.67 vs. 0.33 ± 2.83; p = 0.02). No significant changes were observed in serum NO concentrations, erythrocyte GSH levels, and HADS‐D scores (p > 0.05). Conclusions Based on the findings of the present study, NAC supplementation for 8 weeks decreased lipid peroxidation and improved anxiety symptoms in MS patients. The aforementioned results suggest that adjunctive therapy with NAC can be considered an effective strategy for MS management. Further randomized controlled studies are warranted. N‐acetylcysteine (NAC) supplementation for 8 weeks decreased lipid peroxidation and improved anxiety symptoms in multiple sclerosis (MS) patients. The aforementioned results suggest that adjunctive therapy with NAC can be considered an effective strategy for MS management. |
Author | Cheraghian, Bahman Majdinasab, Nastaran Khalatbari Mohseni, Golsa Hosseini, Seyed Ahmad |
AuthorAffiliation | 3 Department of Neurology, School of Medicine Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran 1 Nutrition and Metabolic Diseases Research Center Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran 2 Department of Nutrition, School of Allied Medical Sciences Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran 4 Department of Statistics and Epidemiology, School of Public Health Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran |
AuthorAffiliation_xml | – name: 1 Nutrition and Metabolic Diseases Research Center Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran – name: 3 Department of Neurology, School of Medicine Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran – name: 2 Department of Nutrition, School of Allied Medical Sciences Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran – name: 4 Department of Statistics and Epidemiology, School of Public Health Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran |
Author_xml | – sequence: 1 givenname: Golsa surname: Khalatbari Mohseni fullname: Khalatbari Mohseni, Golsa organization: Ahvaz Jundishapur University of Medical Sciences – sequence: 2 givenname: Seyed Ahmad orcidid: 0000-0002-9075-4126 surname: Hosseini fullname: Hosseini, Seyed Ahmad email: seyedahmadhosseini@yahoo.com organization: Ahvaz Jundishapur University of Medical Sciences – sequence: 3 givenname: Nastaran surname: Majdinasab fullname: Majdinasab, Nastaran organization: Ahvaz Jundishapur University of Medical Sciences – sequence: 4 givenname: Bahman surname: Cheraghian fullname: Cheraghian, Bahman organization: Ahvaz Jundishapur University of Medical Sciences |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37386885$$D View this record in MEDLINE/PubMed |
BookMark | eNp9ks1u1DAQgCNUREvphQdAlrgg1C3-SezkhFDVQqWqIAQSN8txJq2XxA62t-3eKp6AZ-RJmO2Wqq0QByuJ883nmfE8LTZ88FAUzxndY5TyN36KfI9xIemjYotXqpwxJb5t3HnfLHZSmlOEV0uUT4pNoUQt67raKn4e9D3YnEjoycnvq1_GQl4OdpkyOA8keBIuXWeyOweScoSUSOvCaOJ3iGmXdDCt9lzwu8T4DtelQwFJy3HKYUzEeTJhNHg84sLlMzIuhuymAW12gBiSS8-Kx70ZEuzcPLeLr4cHX_Y_zI4_vj_af3c8s5JKOuMgem4MbxvZ866l0tSUdqKp8ZPWFZOgWlappu-kVI0xqjIWgQrKsmemAbFdHK29XTBzPUWHVSx1ME5fb4R4qk3MDtPS0Cjgqmpow01phDVtbbCfHWOmli1j6Hq7dk2LdoTOYn3RDPek9_94d6ZPw7lmtGwkrRUaXt0YYvixgJT16JKFYTAewiJpXgs8UVWSIvryAToPi-ixV0hJoZgoaYXUi7sp3eby964ReL0GLLY9RehvEUb1apb0apb09SwhTB_A1mW8yLAqxw3_DmHrkAs3wPI_cn3y6TNfx_wBNdTefQ |
CitedBy_id | crossref_primary_10_1016_j_heliyon_2024_e40097 crossref_primary_10_1002_jdn_10392 crossref_primary_10_1016_j_canlet_2024_217405 crossref_primary_10_1007_s00702_024_02792_0 crossref_primary_10_3390_biom14101266 crossref_primary_10_3390_jpm14050488 crossref_primary_10_1016_j_genhosppsych_2024_10_018 crossref_primary_10_3390_ijms252011024 crossref_primary_10_1038_s41598_023_39668_4 crossref_primary_10_1016_j_heliyon_2024_e26271 crossref_primary_10_1016_j_pharmthera_2025_108825 crossref_primary_10_3390_psychiatryint6010034 crossref_primary_10_1007_s12031_025_02332_9 crossref_primary_10_1515_revneuro_2023_0091 |
Cites_doi | 10.1016/j.redox.2015.07.012 10.1097/00007890-200003150-00001 10.3390/nu4101399 10.1177/1756286418819074 10.1007/s00277-011-1404-z 10.1017/S1461145707008401 10.1002/brb3.208 10.1006/niox.2001.0356 10.32598/CJNS.8.29.4 10.1191/1352458505ms1240oa 10.1097/WNF.0000000000000090 10.4314/tjpr.v10i2.66554 10.2174/1871523011312030003 10.7224/1537-2073.2013-013 10.1590/S1516-44462011000400011 10.1016/j.bbagen.2013.04.016 10.1179/1351000211Y.0000000007 10.1186/1477-7525-1-1 10.1016/S1474-4422(02)00102-3 10.1155/2017/3175358 10.1016/j.mehy.2012.03.021 10.1523/JNEUROSCI.21-10-03322.2001 10.1186/1471-244X-13-196 10.4103/0974-7753.100090 10.5414/CNP59441 10.2174/1570159X11666131120223530 10.1002/ana.20736 10.1371/journal.pone.0054163 10.1016/j.jad.2011.06.005 10.1016/j.jns.2008.06.029 10.1001/archgenpsychiatry.2009.60 10.1177/1352458520970841 10.1016/j.bbadis.2010.06.011 10.1199/tab.0142 10.1016/j.pnpbp.2009.01.001 10.1089/cap.2012.0066 10.1503/jpn.100057 10.1016/j.clinbiochem.2011.09.021 10.1155/2012/240146 10.1016/S0753-3322(00)88859-9 10.1159/000306591 10.3109/00207454.2013.801844 10.1016/j.msard.2017.11.003 10.1016/j.clinbiochem.2012.01.023 10.1080/10715762.2018.1468564 10.1002/jnr.10408 10.1016/S0376-8716(99)00040-X 10.1371/journal.pone.0065184 10.1586/ern.10.7 10.1155/2012/609421 10.1016/j.tips.2013.01.001 10.1089/152308602753625988 10.1016/j.jns.2012.07.045 10.1159/000355040 10.1016/j.biopsych.2008.04.022 10.1016/j.jad.2010.08.001 10.1016/j.bbagen.2012.11.016 10.1186/1740-2557-2-4 10.2147/NDT.S241497 10.1093/jn/138.10.1872 10.1186/1471-2377-13-128 |
ContentType | Journal Article |
Copyright | 2023 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology. 2023 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology. 2023. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2023 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology. – notice: 2023 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology. – notice: 2023. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 24P AAYXX CITATION NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PRINS PSYQQ 7X8 5PM DOA |
DOI | 10.1002/npr2.12360 |
DatabaseName | Wiley Online Library Open Access CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Psychology ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | PubMed Publicly Available Content Database MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Wiley Online Library Open Access (WRLC) url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
DocumentTitleAlternate | Khalatbari Mohseni et al |
EISSN | 2574-173X |
EndPage | 390 |
ExternalDocumentID | oai_doaj_org_article_e97e2759092a4a3cab8a257d11a86b11 PMC10496087 37386885 10_1002_npr2_12360 NPR212360 |
Genre | researchArticle Journal Article |
GeographicLocations | Iran Switzerland |
GeographicLocations_xml | – name: Switzerland – name: Iran |
GrantInformation_xml | – fundername: Ahvaz Jundishapur University of Medical Sciences funderid: NRC‐9625 – fundername: Ahvaz Jundishapur University of Medical Sciences grantid: NRC-9625 – fundername: ; grantid: NRC‐9625 |
GroupedDBID | 0R~ 1OC 24P 7X7 8FI 8FJ AAMMB ABDBF ABUWG ACCMX ACGFS ACUHS ACXQS ADBBV ADKYN ADPDF ADZMN AEFGJ AFKRA AGXDD AIDQK AIDYY ALMA_UNASSIGNED_HOLDINGS ALUQN AVUZU BCNDV BENPR BPHCQ BVXVI CCPQU EBS EJD FYUFA GROUPED_DOAJ HMCUK IAO IHR INH IPY ITC M~E O9- OK1 OVD OVEED PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSYQQ RPM TEORI UKHRP WIN AAHHS AAYXX ACCFJ AEEZP AEQDE AIWBW AJBDE ALIPV CITATION NPM 3V. 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c6060-2e3f2aa2b96f2db06a800d3986f208516e7b1579fd6679aa75ac00d5e44f1a9e3 |
IEDL.DBID | 24P |
ISSN | 2574-173X |
IngestDate | Wed Aug 27 01:30:13 EDT 2025 Thu Aug 21 18:36:24 EDT 2025 Fri Jul 11 03:40:21 EDT 2025 Wed Aug 13 07:48:14 EDT 2025 Wed Feb 19 02:22:55 EST 2025 Tue Jul 01 03:07:52 EDT 2025 Thu Apr 24 23:00:00 EDT 2025 Wed Aug 20 07:27:17 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | anxiety antioxidant glutathione multiple sclerosis depression oxidative stress N-acetylcysteine |
Language | English |
License | Attribution-NonCommercial-NoDerivs 2023 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c6060-2e3f2aa2b96f2db06a800d3986f208516e7b1579fd6679aa75ac00d5e44f1a9e3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
ORCID | 0000-0002-9075-4126 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fnpr2.12360 |
PMID | 37386885 |
PQID | 2863713405 |
PQPubID | 4378887 |
PageCount | 9 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_e97e2759092a4a3cab8a257d11a86b11 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10496087 proquest_miscellaneous_2832577560 proquest_journals_2863713405 pubmed_primary_37386885 crossref_primary_10_1002_npr2_12360 crossref_citationtrail_10_1002_npr2_12360 wiley_primary_10_1002_npr2_12360_NPR212360 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | September 2023 |
PublicationDateYYYYMMDD | 2023-09-01 |
PublicationDate_xml | – month: 09 year: 2023 text: September 2023 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Hoboken |
PublicationTitle | Neuropsychopharmacology reports |
PublicationTitleAlternate | Neuropsychopharmacol Rep |
PublicationYear | 2023 |
Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc Wiley |
Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc – name: Wiley |
References | 2010; 10 2012; 2012 2015; 38 2012; 321 2010; 14 2017; 4 2019; 12 2013; 123 2020; 16 2003; 59 2011; 10 2011; 15 2013; 8 2007; 32 2011; 16 2014; 21 2010; 61 2014; 4 2011; 129 2013; 13 2013; 12 2000; 54 2014; 16 1999; 57 2003; 1 2008; 64 2008; 274 2012; 22 2014; 12 2009; 66 2011; 135 2015; 6 2013; 1830 2017; 2017 2000; 69 2006; 59 2002; 1 2011; 33 2002; 4 2008; 11 2011; 36 2012; 79 2011; 9 2001; 21 2018; 19 2009; 33 2012; 91 2001; 5 2013; 34 2022; 8 2020; 26 2002; 70 2011; 1812 2008; 138 2018; 52 2005; 2 2012; 45 2012; 4 2009; 109 2005; 11 e_1_2_12_4_1 e_1_2_12_6_1 e_1_2_12_19_1 Hara Y (e_1_2_12_47_1) 2017; 4 e_1_2_12_2_1 e_1_2_12_38_1 e_1_2_12_20_1 e_1_2_12_41_1 e_1_2_12_66_1 Krotenko N (e_1_2_12_17_1) 2009; 109 e_1_2_12_43_1 e_1_2_12_64_1 e_1_2_12_24_1 e_1_2_12_45_1 e_1_2_12_26_1 e_1_2_12_62_1 e_1_2_12_60_1 Bulut M (e_1_2_12_22_1) 2007; 32 e_1_2_12_28_1 e_1_2_12_49_1 e_1_2_12_31_1 e_1_2_12_52_1 e_1_2_12_33_1 e_1_2_12_35_1 e_1_2_12_56_1 e_1_2_12_37_1 e_1_2_12_58_1 e_1_2_12_14_1 e_1_2_12_12_1 e_1_2_12_8_1 e_1_2_12_10_1 e_1_2_12_50_1 e_1_2_12_3_1 e_1_2_12_5_1 e_1_2_12_18_1 e_1_2_12_16_1 e_1_2_12_39_1 e_1_2_12_42_1 e_1_2_12_65_1 e_1_2_12_21_1 e_1_2_12_44_1 e_1_2_12_63_1 e_1_2_12_23_1 e_1_2_12_46_1 e_1_2_12_25_1 e_1_2_12_48_1 e_1_2_12_67_1 e_1_2_12_61_1 e_1_2_12_40_1 Atakisi O (e_1_2_12_54_1) 2010; 14 e_1_2_12_27_1 e_1_2_12_29_1 e_1_2_12_30_1 e_1_2_12_53_1 e_1_2_12_32_1 e_1_2_12_55_1 e_1_2_12_34_1 Bayır A (e_1_2_12_57_1) 2011; 15 e_1_2_12_36_1 e_1_2_12_59_1 e_1_2_12_15_1 e_1_2_12_13_1 e_1_2_12_11_1 e_1_2_12_7_1 e_1_2_12_51_1 e_1_2_12_9_1 |
References_xml | – volume: 69 start-page: 703 issue: 5 year: 2000 end-page: 4 article-title: N‐acetylcysteine: not simply a glutathione precusor publication-title: Transplantation – volume: 26 start-page: 1816 issue: 14 year: 2020 end-page: 21 article-title: Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS publication-title: Mult Scler J – volume: 123 start-page: 776 issue: 11 year: 2013 end-page: 82 article-title: Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with relapsing‐remitting multiple sclerosis publication-title: Int J Neurosci – volume: 274 start-page: 48 issue: 1–2 year: 2008 end-page: 53 article-title: Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity publication-title: J Neurol Sci – volume: 21 start-page: 13 issue: 1 year: 2014 end-page: 20 article-title: Glutathione homeostasis disruption of erythrocytes, but not glutathione peroxidase activity change, is closely accompanied with neurological and radiological scoring of acute CNS inflammation publication-title: Neuroimmunomodulation – volume: 45 start-page: 440 issue: 6 year: 2012 end-page: 4 article-title: Peripheral oxidative stress in relapsing–remitting multiple sclerosis publication-title: Clin Biochem – volume: 2012 start-page: 1 year: 2012 end-page: 13 article-title: Preclinical and clinical evidence of antioxidant effects of antidepressant agents: implications for the pathophysiology of major depressive disorder publication-title: Oxid Med Cell Longev – volume: 4 start-page: 108 issue: 2 year: 2014 end-page: 22 article-title: N‐acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities publication-title: Brain Behav – volume: 34 start-page: 167 issue: 3 year: 2013 end-page: 77 article-title: The promise of N‐acetylcysteine in neuropsychiatry publication-title: Trends Pharmacol Sci – volume: 10 start-page: 141 year: 2011 end-page: 6 article-title: Pharmacodynamic effect of N‐acetylcysteine as adjunctive therapy in mild systemic lupus erythematosus patients publication-title: Trop J Pharm Res – volume: 2012 start-page: 1 year: 2012 end-page: 12 article-title: Recent advances in the treatment of neurodegenerative diseases based on GSH delivery systems publication-title: Oxid Med Cell Longev – volume: 16 start-page: 1265 year: 2020 end-page: 78 article-title: Evidence for a beneficial effect of oral N‐acetylcysteine on functional outcomes and inflammatory biomarkers in patients with acute ischemic stroke publication-title: Neuropsychiatr Dis Treat – volume: 70 start-page: 580 issue: 4 year: 2002 end-page: 7 article-title: Nitric oxide synthase is present in the cerebrospinal fluid of patients with active multiple sclerosis and is associated with increases in cerebrospinal fluid protein nitrotyrosine and S‐nitrosothiols and with changes in glutathione levels publication-title: J Neurosci Res – volume: 13 start-page: 1 issue: 1 year: 2013 end-page: 13 article-title: Incidence and prevalence of multiple sclerosis in Europe: a systematic review publication-title: BMC Neurol – volume: 36 start-page: 78 issue: 2 year: 2011 end-page: 86 article-title: N‐acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action publication-title: J Psychiatry Neurosci – volume: 64 start-page: 468 issue: 6 year: 2008 end-page: 75 article-title: N‐acetyl cysteine for depressive symptoms in bipolar disorder—a double‐blind randomized placebo‐controlled trial publication-title: Biol Psychiatry – volume: 135 start-page: 389 issue: 1–3 year: 2011 end-page: 94 article-title: The efficacy of N‐acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial publication-title: J Affect Disord – volume: 2017 start-page: 1 year: 2017 end-page: 9 article-title: Depression treatment among adults with multiple sclerosis and depression in ambulatory care settings in the United States publication-title: Mult Scler Int – volume: 2 start-page: 4 issue: 1 year: 2005 article-title: N‐acetyl‐L‐cysteine ameliorates the inflammatory disease process in experimental autoimmune encephalomyelitis in Lewis rats publication-title: J Autoimmune Dis – volume: 8 start-page: 104 issue: 2 year: 2022 end-page: 16 article-title: The time‐trend of multiple sclerosis incidence and prevalence in Khuzestan Province, Iran publication-title: Caspian J Neurol Sci – volume: 32 start-page: 435 issue: 6 year: 2007 end-page: 8 article-title: Malondialdehyde levels in adult attention‐deficit hyperactivity disorder publication-title: J Psychiatry Neurosci – volume: 59 start-page: 441 issue: 6 year: 2003 end-page: 6 article-title: N‐acetylcysteine reduces malondialdehyde levels in chronic hemodialysis patients–a pilot study publication-title: Clin Nephrol – volume: 109 start-page: 53 issue: 7 Suppl 2 year: 2009 end-page: 6 article-title: Parameters of antioxidant protection in multiple sclerosis publication-title: Zh Nevrol Psikhiatr Im S S Korsakova – volume: 11 start-page: 851 issue: 6 year: 2008 end-page: 76 article-title: Oxidative stress in psychiatric disorders: evidence base and therapeutic implications publication-title: Int J Neuropsychopharmacol – volume: 16 start-page: 166 issue: 4 year: 2011 end-page: 72 article-title: Aminoguanidine and N‐acetyl‐cysteine supress oxidative and nitrosative stress in EAE rat brains publication-title: Redox Rep – volume: 52 start-page: 751 issue: 7 year: 2018 end-page: 62 article-title: N‐acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why publication-title: Free Radic Res – volume: 8 issue: 6 year: 2013 article-title: Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis publication-title: PLoS One – volume: 138 start-page: 1872 issue: 10 year: 2008 end-page: 9 article-title: N‐acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis publication-title: J Nutr – volume: 13 start-page: 1 issue: 1 year: 2013 end-page: 7 article-title: A randomized double blind placebo controlled clinical trial of N‐acetylcysteine added to risperidone for treating autistic disorders publication-title: BMC Psychiatry – volume: 4 start-page: 201 issue: 3 year: 2017 end-page: 6 article-title: Evaluation of the neuroprotective potential of N‐acetylcysteine for prevention and treatment of cognitive aging and dementia publication-title: J Prev Alzheimers Dis – volume: 66 start-page: 756 issue: 7 year: 2009 end-page: 63 article-title: N‐acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double‐blind, placebo‐controlled study publication-title: Arch Gen Psychiatry – volume: 1830 start-page: 3350 issue: 5 year: 2013 end-page: 3 article-title: Glutathione and glutathione analogues; therapeutic potentials publication-title: Biochim Biophys Acta – volume: 4 start-page: 176 issue: 3 year: 2012 end-page: 8 article-title: N‐acetylcysteine in the treatment of trichotillomania publication-title: Int J Trichology – volume: 45 start-page: 26 issue: 1–2 year: 2012 end-page: 30 article-title: Oxidative modification of patient's plasma proteins and its role in pathogenesis of multiple sclerosis publication-title: Clin Biochem – volume: 1 start-page: 232 issue: 4 year: 2002 end-page: 41 article-title: The role of nitric oxide in multiple sclerosis publication-title: Lancet Neurol – volume: 14 start-page: 19 issue: 1 year: 2010 end-page: 23 article-title: Effects of reduced glutathione on nitric oxide level, total antioxidant and oxidant capacity and adenosine deaminase activity publication-title: Eur Rev Med Pharmacol Sci – volume: 4 start-page: 1399 issue: 10 year: 2012 end-page: 440 article-title: Dysregulation of glutathione homeostasis in neurodegenerative diseases publication-title: Nutrients – volume: 12 start-page: 193 issue: 2 year: 2014 end-page: 204 article-title: Oxidative imbalance and anxiety disorders publication-title: Curr Neuropharmacol – volume: 8 issue: 1 year: 2013 article-title: Amelioration of acute sequelae of blast induced mild traumatic brain injury by N‐acetyl cysteine: a double‐blind, placebo controlled study publication-title: PLoS One – volume: 12 start-page: 223 issue: 3 year: 2013 end-page: 8 article-title: N‐acetylcysteine versus placebo for treating nail biting, a double blind randomized placebo controlled clinical trial publication-title: Antiinflamm Antiallergy Agents Med Chem – volume: 12 year: 2019 article-title: Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon‐β1a‐treated multiple sclerosis publication-title: Ther Adv Neurol Disord – volume: 19 start-page: 35 year: 2018 end-page: 9 article-title: The prevalence of anxiety and associated factors in persons with multiple sclerosis publication-title: Mult Scler Relat Disord – volume: 1812 start-page: 141 issue: 2 year: 2011 end-page: 50 article-title: Radical changes in multiple sclerosis pathogenesis publication-title: Biochim Biophys Acta – volume: 21 start-page: 3322 issue: 10 year: 2001 end-page: 31 article-title: Pyruvate released by astrocytes protects neurons from copper‐catalyzed cysteine neurotoxicity publication-title: J Neurosci – volume: 5 start-page: 349 issue: 4 year: 2001 end-page: 60 article-title: N‐acetylcysteine inhibits in vivo nitric oxide production by inducible nitric oxide synthase publication-title: Nitric Oxide – volume: 91 start-page: 1097 issue: 7 year: 2012 end-page: 105 article-title: N‐acetylcysteine reduces oxidative stress in sickle cell patients publication-title: Ann Hematol – volume: 9 year: 2011 article-title: Glutathione publication-title: Arabidopsis Book – volume: 79 start-page: 8 issue: 1 year: 2012 end-page: 12 article-title: N‐acetyl‐cysteine in the treatment of Parkinson's disease. What are we waiting for? publication-title: Med Hypotheses – volume: 1830 start-page: 4117 issue: 8 year: 2013 end-page: 29 article-title: The chemistry and biological activities of N‐acetylcysteine publication-title: Biochim Biophys Acta – volume: 321 start-page: 49 issue: 1–2 year: 2012 end-page: 53 article-title: Oxidative stress in multiple sclerosis patients in clinical remission: association with the expanded disability status scale publication-title: J Neurol Sci – volume: 38 start-page: 127 issue: 4 year: 2015 end-page: 31 article-title: Tolerability and safety of combined glatiramer acetate and N‐acetylcysteine in relapsing‐remitting multiple sclerosis publication-title: Clin Neuropharmacol – volume: 33 start-page: 363 issue: 2 year: 2009 end-page: 6 article-title: Correlation between lipid peroxidation‐induced TBARS level and disease severity in obsessive–compulsive disorder publication-title: Prog Neuropsychopharmacol Biol Psychiatry – volume: 54 start-page: 100 issue: 2 year: 2000 end-page: 2 article-title: Epidemiologic studies of multiple sclerosis: a review publication-title: Biomed Pharmacother – volume: 16 start-page: 105 issue: 2 year: 2014 end-page: 9 article-title: Validation of mood measures for people with multiple sclerosis publication-title: Int J MS Care – volume: 57 start-page: 61 issue: 1 year: 1999 end-page: 7 article-title: Protective effect of N‐acetylcysteine on reduced glutathione, reduced glutathione‐related enzymes and lipid peroxidation in methanol intoxication publication-title: Drug Alcohol Depend – volume: 15 start-page: 1 issue: 1 year: 2011 end-page: 190 article-title: Effects of N‐acetylcysteine on the erythrocyte and liver cholinesterase, nitric oxide and malondialdehyde levels in acute organophosphate toxicity publication-title: Crit Care – volume: 6 start-page: 198 year: 2015 end-page: 205 article-title: Effects of N‐acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers: a comparative crossover study publication-title: Redox Biol – volume: 129 start-page: 317 issue: 1–3 year: 2011 end-page: 20 article-title: N‐acetyl cysteine add‐on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo‐controlled trial publication-title: J Affect Disord – volume: 11 start-page: 677 issue: 6 year: 2005 end-page: 82 article-title: Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity publication-title: Mult Scler J – volume: 10 start-page: 421 issue: 3 year: 2010 end-page: 40 article-title: Environmental risk factors in multiple sclerosis publication-title: Expert Rev Neurother – volume: 4 start-page: 221 issue: 1 year: 2002 end-page: 6 article-title: N‐acetylcysteine negatively modulates nitric oxide production in endotoxin‐treated rats through inhibition of NF‐κB activation publication-title: Antioxid Redox Signal – volume: 59 start-page: 478 issue: 3 year: 2006 end-page: 89 article-title: Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients publication-title: Ann Neurol – volume: 22 start-page: 472 issue: 6 year: 2012 end-page: 3 article-title: Treatment with adjunctive N‐acetylcysteine in an adolescent with selective serotonin reuptake inhibitor‐resistant anxiety publication-title: J Child Adolesc Psychopharmacol – volume: 1 start-page: 1 issue: 1 year: 2003 end-page: 5 article-title: The hospital anxiety and depression scale (HADS): translation and validation study of the Iranian version publication-title: Health Qual Life Outcomes – volume: 61 start-page: 210 issue: 4 year: 2010 end-page: 4 article-title: Relationship of possible stress‐related biochemical markers to oxidative/antioxidative status in obsessive‐compulsive disorder publication-title: Neuropsychobiology – volume: 33 start-page: 374 issue: 4 year: 2011 end-page: 8 article-title: N‐acetylcysteine for major depressive episodes in bipolar disorder = N‐acetilcisteína para o tratamento de episódios de depressão maior no transtorno bipolar publication-title: Braz J Psychiatry – ident: e_1_2_12_50_1 doi: 10.1016/j.redox.2015.07.012 – ident: e_1_2_12_51_1 doi: 10.1097/00007890-200003150-00001 – ident: e_1_2_12_16_1 doi: 10.3390/nu4101399 – volume: 4 start-page: 201 issue: 3 year: 2017 ident: e_1_2_12_47_1 article-title: Evaluation of the neuroprotective potential of N‐acetylcysteine for prevention and treatment of cognitive aging and dementia publication-title: J Prev Alzheimers Dis – ident: e_1_2_12_67_1 doi: 10.1177/1756286418819074 – ident: e_1_2_12_38_1 doi: 10.1007/s00277-011-1404-z – ident: e_1_2_12_19_1 doi: 10.1017/S1461145707008401 – ident: e_1_2_12_35_1 doi: 10.1002/brb3.208 – ident: e_1_2_12_55_1 doi: 10.1006/niox.2001.0356 – ident: e_1_2_12_9_1 doi: 10.32598/CJNS.8.29.4 – ident: e_1_2_12_12_1 doi: 10.1191/1352458505ms1240oa – ident: e_1_2_12_39_1 doi: 10.1097/WNF.0000000000000090 – ident: e_1_2_12_43_1 doi: 10.4314/tjpr.v10i2.66554 – ident: e_1_2_12_59_1 doi: 10.2174/1871523011312030003 – ident: e_1_2_12_40_1 doi: 10.7224/1537-2073.2013-013 – ident: e_1_2_12_65_1 doi: 10.1590/S1516-44462011000400011 – ident: e_1_2_12_31_1 doi: 10.1016/j.bbagen.2013.04.016 – ident: e_1_2_12_32_1 doi: 10.1179/1351000211Y.0000000007 – ident: e_1_2_12_41_1 doi: 10.1186/1477-7525-1-1 – ident: e_1_2_12_53_1 doi: 10.1016/S1474-4422(02)00102-3 – ident: e_1_2_12_11_1 doi: 10.1155/2017/3175358 – ident: e_1_2_12_49_1 doi: 10.1016/j.mehy.2012.03.021 – ident: e_1_2_12_48_1 doi: 10.1523/JNEUROSCI.21-10-03322.2001 – volume: 14 start-page: 19 issue: 1 year: 2010 ident: e_1_2_12_54_1 article-title: Effects of reduced glutathione on nitric oxide level, total antioxidant and oxidant capacity and adenosine deaminase activity publication-title: Eur Rev Med Pharmacol Sci – ident: e_1_2_12_60_1 doi: 10.1186/1471-244X-13-196 – ident: e_1_2_12_62_1 doi: 10.4103/0974-7753.100090 – ident: e_1_2_12_45_1 doi: 10.5414/CNP59441 – volume: 32 start-page: 435 issue: 6 year: 2007 ident: e_1_2_12_22_1 article-title: Malondialdehyde levels in adult attention‐deficit hyperactivity disorder publication-title: J Psychiatry Neurosci – ident: e_1_2_12_21_1 doi: 10.2174/1570159X11666131120223530 – ident: e_1_2_12_25_1 doi: 10.1002/ana.20736 – ident: e_1_2_12_34_1 doi: 10.1371/journal.pone.0054163 – ident: e_1_2_12_63_1 doi: 10.1016/j.jad.2011.06.005 – ident: e_1_2_12_3_1 doi: 10.1016/j.jns.2008.06.029 – ident: e_1_2_12_61_1 doi: 10.1001/archgenpsychiatry.2009.60 – ident: e_1_2_12_8_1 doi: 10.1177/1352458520970841 – ident: e_1_2_12_26_1 doi: 10.1016/j.bbadis.2010.06.011 – ident: e_1_2_12_29_1 doi: 10.1199/tab.0142 – ident: e_1_2_12_23_1 doi: 10.1016/j.pnpbp.2009.01.001 – volume: 15 start-page: 1 issue: 1 year: 2011 ident: e_1_2_12_57_1 article-title: Effects of N‐acetylcysteine on the erythrocyte and liver cholinesterase, nitric oxide and malondialdehyde levels in acute organophosphate toxicity publication-title: Crit Care – ident: e_1_2_12_58_1 doi: 10.1089/cap.2012.0066 – ident: e_1_2_12_37_1 doi: 10.1503/jpn.100057 – ident: e_1_2_12_4_1 doi: 10.1016/j.clinbiochem.2011.09.021 – ident: e_1_2_12_27_1 doi: 10.1155/2012/240146 – ident: e_1_2_12_5_1 doi: 10.1016/S0753-3322(00)88859-9 – ident: e_1_2_12_24_1 doi: 10.1159/000306591 – ident: e_1_2_12_42_1 doi: 10.3109/00207454.2013.801844 – ident: e_1_2_12_10_1 doi: 10.1016/j.msard.2017.11.003 – ident: e_1_2_12_14_1 doi: 10.1016/j.clinbiochem.2012.01.023 – ident: e_1_2_12_52_1 doi: 10.1080/10715762.2018.1468564 – ident: e_1_2_12_15_1 doi: 10.1002/jnr.10408 – ident: e_1_2_12_44_1 doi: 10.1016/S0376-8716(99)00040-X – ident: e_1_2_12_2_1 doi: 10.1371/journal.pone.0065184 – ident: e_1_2_12_6_1 doi: 10.1586/ern.10.7 – ident: e_1_2_12_20_1 doi: 10.1155/2012/609421 – ident: e_1_2_12_36_1 doi: 10.1016/j.tips.2013.01.001 – ident: e_1_2_12_56_1 doi: 10.1089/152308602753625988 – ident: e_1_2_12_13_1 doi: 10.1016/j.jns.2012.07.045 – ident: e_1_2_12_18_1 doi: 10.1159/000355040 – ident: e_1_2_12_64_1 doi: 10.1016/j.biopsych.2008.04.022 – ident: e_1_2_12_66_1 doi: 10.1016/j.jad.2010.08.001 – ident: e_1_2_12_28_1 doi: 10.1016/j.bbagen.2012.11.016 – ident: e_1_2_12_33_1 doi: 10.1186/1740-2557-2-4 – ident: e_1_2_12_46_1 doi: 10.2147/NDT.S241497 – volume: 109 start-page: 53 issue: 7 year: 2009 ident: e_1_2_12_17_1 article-title: Parameters of antioxidant protection in multiple sclerosis publication-title: Zh Nevrol Psikhiatr Im S S Korsakova – ident: e_1_2_12_30_1 doi: 10.1093/jn/138.10.1872 – ident: e_1_2_12_7_1 doi: 10.1186/1471-2377-13-128 |
SSID | ssj0002000234 |
Score | 2.3513799 |
Snippet | Aim
N‐acetylcysteine (NAC), a thiol‐containing antioxidant and glutathione (GSH) precursor, attenuates oxidative stress, and possibly improves psychiatric... N-acetylcysteine (NAC), a thiol-containing antioxidant and glutathione (GSH) precursor, attenuates oxidative stress, and possibly improves psychiatric... Aim N‐acetylcysteine (NAC), a thiol‐containing antioxidant and glutathione (GSH) precursor, attenuates oxidative stress, and possibly improves psychiatric... N‐acetylcysteine (NAC) supplementation for 8 weeks decreased lipid peroxidation and improved anxiety symptoms in multiple sclerosis (MS) patients. The... Abstract Aim N‐acetylcysteine (NAC), a thiol‐containing antioxidant and glutathione (GSH) precursor, attenuates oxidative stress, and possibly improves... |
SourceID | doaj pubmedcentral proquest pubmed crossref wiley |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 382 |
SubjectTerms | antioxidant Antioxidants Anxiety Biomarkers Blood Brain research Chronic illnesses depression Disease Drug dosages Glutathione Lipid peroxidation Mental depression Multiple sclerosis Neurological disorders N‐acetylcysteine Obsessive compulsive disorder Original Oxidative stress |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlp15K3902LSotgZZ1Y8uyHse2NIRCl6UkkJuRLIluSORlvYHsreQX5Df2l3QkeZ1dGtpLDzZ-jMVIGjEz1sw3CL0tSxoKv5mMcJNnoG9Jpp2FU0Ed5aVmTods5G8TdnhMv55UJxulvkJMWIIHTgO3byW3hFcyl0RRVTZKCwViZopCCaZTVi_ovA1n6jRurwVlRAc8UrLv5wvyIUCN5FsaKAL132Zd_hkkuWm8Ru1zcB_d681G_DGx-wDdsf4h2psm3OnVGB_dpFF1Y7yHpzeI1KtH6CphFHe4dXjy6-e1auxyddYEEGcwMnHrcXs5MxECHKfkERzS8kPkzgKaG6Jl_Rgrb-C4DJGeuFudz5fteYdnHvf4rB0OP3bxOkwRd8AtjMKse4yOD74cfT7M-uILWQM-TZ4RWzqiFNGSOWJ0zhSYlqaUAm6DmcYs10XFpTOMcakUr1QDBJWl1BVK2vIJ2vGtt88QNsLxiglXUXB_pMmlzitw1GRIgKBK6hF6t56QuumRyUOBjLM6YSqTOkxeHSdvhN4MtPOEx3Er1acwrwNFwNCOD0Cy6l6y6n9J1gjtrqWi7hd2VxPBypB-m1cj9Hp4DUsy7LMob9uLQFNCO9Bl4ONpEqKBkwAkxYSAr8WWeG2xuv3Gz35E2G9wnMHdFHyE3kdJ_Ev_68n0O4lXz__HSLxAdwkspxRat4t2losL-xJssaV-FZfdbzhDNG4 priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9RAEF-0vvgi1s_YKitKQbnYZLPZjydRsRTB45AW7i3sZjf1oE3OyxV6b-Jf4N_oX-LMJpfzsPQhIR-TsJuZ2Z3ZzPyGkNdZxrHwm4uZdEkM8y2LbeVhl_KKy8yKymI28texOD7lX6b5tF9wa_uwyvWYGAZq15S4Rn7IlMgw7zHJ389_xFg1Cv-u9iU0bpM7CF2GIV1yKoc1FhbgXPiASsoO6_mCvUPAkWRrHgpw_dfZmP-HSv5rwoY56Og-udcbj_RDx-1dcsvXD8jBpEOfXo3oySaZqh3RAzrZ4FKvHpJfHVJxS5uKjv_8_G1Kv1ydlwjlDKYmbWraXM1cAAKnXQoJxeR8jN9ZwOuGmNl6RE3tYLvCeE_ari7my-aipbOa9iitLcXlXboOVqQttBa-wqx9RE6PPp98Oo77EgxxCZ5NEjOfVcwYZrWomLOJMGBgukwrOEVjTXhp01zqygkhtTEyNyUQ5J7zKjXaZ4_JTt3U_imhTlUyF6rKOThB2iXaJjm4axrTILjRNiJv1gwpyh6fHMtknBcdsjIrkHlFYF5EXg208w6V41qqj8jXgQKRtMOFZnFW9IpZeC09k7lONDPcZKWxysAw5tLUKGHTNCL7a6koevVui40wRuTlcBsUE_-2mNo3l0iTwXugy9COJ50QDS1BOCmhFDyttsRrq6nbd-rZ9wD-De4zOJ1KRuRtkMQb-l-MJ99YOHp2cyf2yF0GitKFzu2TneXi0j8HW2tpXwSF-gtfLSxB priority: 102 providerName: ProQuest |
Title | Effects of N‐acetylcysteine on oxidative stress biomarkers, depression, and anxiety symptoms in patients with multiple sclerosis |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fnpr2.12360 https://www.ncbi.nlm.nih.gov/pubmed/37386885 https://www.proquest.com/docview/2863713405 https://www.proquest.com/docview/2832577560 https://pubmed.ncbi.nlm.nih.gov/PMC10496087 https://doaj.org/article/e97e2759092a4a3cab8a257d11a86b11 |
Volume | 43 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlZ3da9swEMBFaV_2Mva9bG3Q2ChsxKsty_qAvTRbQxkshNFC3oxky12gtUOcQvNW9hfsb9xfsjvZcRpWBnuI8-GTka276E6--5mQd3HM8cFvecBkHgYw37LAFg42ES-4jK0oLFYjfxuL03P-dZpMd8indS1Mw4foFtzQMvz_NRq4sfXRHWjofME-IjsEAvY9rK1Fcj7jk26FhXmYC95WBrXkQSTjaccnZUeb5lszkgf33-dt_p00edeZ9bPR6BF52LqR9LgZ98dkx5VPyOGk4VCvBvRsU1ZVD-ghnWwI1aun5GfDLK5pVdDx79tfJnPL1WWGUGe4LLQqaXUzyz0SnDbFJBTL9DGTZwGH67JnywE1ZQ6vG8z8pPXqar6srmo6K2nLa60pLvTSddoiraG3cBVm9TNyPjo5-3watA9jCDKIccKAubhgxjCrRcFyGwoDrmYeawVf0W0TTtookbrIhZDaGJmYDAQSx3kRGe3i52S3rEr3ktBcFTIRqkg4hEM6D7UNEwjcNBZEcKNtj7xfD0iataRyfGDGZdowllmKg5f6weuRt53svOFz3Cs1xHHtJJCp7X-oFhdpa6Kp09IxmehQM8NNnBmrDGhOHkVGCRtFPbK_1oq0NfQ6ZUrEWI4bJj3yptsNJor3XUzpqmuUieE4cMrQjxeNEnU9QbCUUApaqy312urq9p5y9sNjwCGQhvBTyR754DXxH-efjiffmf_06n-EX5MHDEyoSanbJ7vLxbU7AB9safve1GArp7JP9o6HX4YjeB-eQNu-X9f4A2oCM_E |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELdG9wAviP8UBhgBk0ANSxzHiR8QYrCpY1tVoU7aW7BjZ6u0JaXpxPqG-AR8Ej4Un4S7_CsV0972kCptLpbdO5_v7LvfEfLS9zkWfjMOC43rwHrLHJ1a-PB4ykNfi1RjNvL-QPQP-OfD4HCF_G5yYTCsstGJpaI2eYJ75BssEj7mPbrB-8k3B6tG4elqU0KjEotdO_8OLlvxbucT8PcVY9tbo499p64q4CRgrLsOs37KlGJaipQZ7QoFNpPxZQRf0f4QNtReEMrUCBFKpcJAJUAQWM5TT0nrQ7vXyCr3wZXpkNXNrcHwS7urw0oAGd7ioLKNbDJlbxHixF1a-coCARdZtf8HZ_5rNJer3vYtcrM2V-mHSr5ukxWb3SHrwwrvet6jo0X6VtGj63S4QMKe3yU_K2zkguYpHfz58UsldjY_SRA8Goxbmmc0Px-bEnqcVkkrFOEAMGJoCs21UbpZj6rMwHWOEaa0mJ9OZvlpQccZrXFhC4obyrQJj6QF9Bb-hXFxjxxcCXvuk06WZ_YhoSZKw0BEacDB7ZLGldoNwEGUmHjBldRd8rphSJzUiOhYmOMkrrCcWYzMi0vmdcmLlnZS4YBcSLWJfG0pELu7_CGfHsW1KoitDC0LA-lKprjyE6UjBYrTeJ6KhPa8LllrpCKuFUoRL8S_S563j0EV4PmOymx-hjQ-tANDhn48qISo7QkCWIkogrejJfFa6uryk2x8XMKNg8MObm4UdsmbUhIvGX8Mc4GVd48uH8Qzcr0_2t-L93YGu4_JDQaTpgrcWyOd2fTMPgFLb6af1tOLkq9XPaP_AtQ3acA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELfGkBAviP8UBhgBk0ANTZzEjh8QAsa0MagqtEl9C3ZsQ6UtKU0n1jfEJ-Dz8HH4JNzlX6mY9raHVm1zsezeH985d78j5EkYRtj4zXhMGN-D_ZZ52ll4CyIXiVBzp7Ea-eOQ7xxE78fxeI38bmthMK2ytYmVoTZFhmfkA5bwEOse_XjgmrSI0db2q-k3DztI4ZPWtp1GLSJ7dvEdwrfy5e4W8PopY9vv9t_ueE2HAS8Dx933mA0dU4ppyR0z2ucK_CcTygS-oi_CrdBBLKQznAuplIhVBgSxjSIXKGlDGPcCuSjCOEAdE2PRne-wCkom6hBR2SCfztgLBDvxV_bAqlXAaf7t_2ma_7rP1f63fZVcaRxX-rqWtGtkzebXyeaoRr5e9On-spCr7NNNOlpiYi9ukJ81SnJJC0eHf378UpmdLw4zhJEGN5cWOS1OJqYCIad1-QpFYADMHZrBcF2-bt6nKjfwOsFcU1oujqbz4qikk5w2CLElxaNl2iZK0hJmC__CpLxJDs6FObfIel7k9g6hJnEi5omLIwjApPGl9mMIFSWWYERK6h551jIkzRpsdGzRcZjWqM4sRealFfN65HFHO60RQU6leoN87SgQxbv6oZh9SRujkFopLBOx9CVTkQozpRMFJtQEgUq4DoIe2WilIm1MS5kuFaFHHnWXwSjgkx6V2-IYaUIYB5YM87hdC1E3E4Sy4kkCdycr4rUy1dUr-eRrBTwOoTsEvInokeeVJJ6x_nQ4-sSqT3fPXsRDcgn0OP2wO9y7Ry4z0Jk6g2-DrM9nx_Y-uHxz_aDSLUo-n7cy_wVs-myQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+N-acetylcysteine+on+oxidative+stress+biomarkers%2C+depression%2C+and+anxiety+symptoms+in+patients+with+multiple+sclerosis&rft.jtitle=Neuropsychopharmacology+reports&rft.au=Khalatbari+Mohseni%2C+Golsa&rft.au=Hosseini%2C+Seyed+Ahmad&rft.au=Majdinasab%2C+Nastaran&rft.au=Cheraghian%2C+Bahman&rft.date=2023-09-01&rft.eissn=2574-173X&rft_id=info:doi/10.1002%2Fnpr2.12360&rft_id=info%3Apmid%2F37386885&rft.externalDocID=37386885 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2574-173X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2574-173X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2574-173X&client=summon |